Euro Ewing Consortium

International Clinical Trials to Improve Survival from Ewing Sarcoma

rEECur - May 2019 update

rEECur - International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma


The GD arm is now closed to recruitment, following the first planned interim analysis. The rEECur data monitoring committee made this recommendation on the basis that the GD regimen is not as promising as the other treatment arms, based on response and progression-free survival. There were no safety concerns.  The outcomes of patients recruited to the GD arm will be presented at ASCO in June and a paper is planned for later this year when all patients recruited to the GD arm have been followed up and their data analysed.

rEECur recruitment thermometer 8May2019
  • The aim of the rEECur trial is to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects.
  • 525 patients will be recruited from across Europe from 2015.

The rEECur trial is progressing well, with patients able to take part in the UK, Spain, Italy, Denmark, France, Norway, Belgium, Finland, Hungary, Poland, The Netherlands, the Czech Republic, Switzerland, Australia and New Zealand. The trial is expected to be to open to patients in Germany soon.

  • 311 patients have been recruited so far

Before any results can be released, we have to wait until we have recruited all the 525 patients and followed them for a period of time to see how they get on with treatment. It will take a number of years to reach the target of 525 patients at which point statisticians will be able to analyse all the information. The data is reviewed regularly by independent bodies to check for any safety concerns. Each person who takes part in the trial provides invaluable data and provides an important contribution Ewing sarcoma research.

  • Over 500 biospecimens have been collected from patients taking part in the trial. These will be used for research.

We are grateful to those patients who have agreed to join this trial, and to their families, and treating clinical teams across Europe

This page will be updated twice a year.